CYT003-QbG10 for Treatment of Allergic Asthma Bronchial

Phase 2

Completed

• Conditions: Allergic Bronchial Asthma
• Interventions: Drug: CYT003-QbG10; Drug: Placebo

• Registration Number: NCT00890734
• Lead Sponsor: Cytos Biotechnology AG

Brief Summary

The purpose of the study is to test whether treatment with CYT003-QbG10 can improve asthma symptoms in patients with allergic bronchial asthma. The active treatment will be compared against placebo.

Detailed Description

Not available

Study Timeline

• Study Start: 2009-04
• Study First Submitted: 2009-04-28
• Study First Submitted QC: 2009-04-29
• Study First Posted: 2009-04-30
• Primary Completion: 2010-04
• Study Completion: 2010-11
• Status Verified: 2012-02
• Last Update Submitted: 2012-02-10
• Last Update Posted: 2012-02-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 63

Inclusion Criteria

• Persistent allergic asthma bronchial requiring long-term treatment with inhaled corticosteroids
• Further criteria as defined in the study protocol

Exclusion Criteria

• Use of oral corticosteroids within past 3 months
• Hospitalization for asthma exacerbation within past 6 months
• Uncontrolled asthma
• Contraindication to any study test or procedure
• Further criteria as defined in the study protocol

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
1	CYT003-QbG10	-
2	Placebo	-

Primary Outcome Measures

Name	Time	Method
Markers for inflammation and asthma	1-3 months

Trial Locations

Locations (1)

Cytos Investigator Sites; 🇩🇪 Luebeck, Berlin, Wiesbaden, Rodgau, Eisenach, Germany